Adams Respiratory Therapeutics Inc

Adams Respiratory Therapeutics — Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)

21 slides from Adams Respiratory Therapeutics's conference presentation, Feb 8, 2007

  1. Slide 1: Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference

    Slide 1: Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference

    Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference February 8, 2007

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

  3. Slide 3: A Specialty Pharmaceutical Company

    Slide 3: A Specialty Pharmaceutical Company

    A Specialty Pharmaceutical Company Adams is focused on: Developing a range of solutions that treat respiratory disease Late-stage development and marketing of differentiated OTC and Rx pharmaceutical brands

  4. Slide 4: Adams' Business Strategy

    Slide 4: Adams' Business Strategy

    Adams' Business Strategy Build internal pipeline by extending guaifenesin platform to other OTC & Rx respiratory segments Access platform technologies to accelerate product development Four - pronged strategy Drive Mucinex(r) brand awareness & market share among professionals and consumers Build Rx

  5. Slide 5: Strong Growth in Revenues

    Slide 5: Strong Growth in Revenues

    12- Months Ended 6- Months Ended Strong Growth in Revenues (in millions) 6/03 12/05 6/04 6/05 YoY Growth 82% CAGR '03-'06 158 % 12/06 6/06 $239.1 $110.3

  6. Slide 6: Mucinex Brand a Category Leader

    Slide 6: Mucinex Brand a Category Leader

    Mucinex(r) Brand a Category Leader Mucinex(r) Brand a Category Leader SE 20's # 3 # 13 DM 20's # 6 # 22 SE 40's # 7 All OTC SKUs All Items Top 500 UPC Dollar Ranking at Drug Outlets (2) Higher ranking SKUs: 6 cigarettes 4 beverages 2 OTC products Source: Information Resources, Inc. (IRI) Brand Ranki

  7. Slide 7: Dollar Market Share for Children's Mucinex and Delsym Continues to Accelerate

    Slide 7: Dollar Market Share for Children's Mucinex and Delsym Continues to Accelerate

    Dollar Market Share for Children's Mucinex(r) and Delsym(r) Continues to Accelerate Source: IRI data for the pediatric and cough syrup segments of the c/c/a/s category for the periods ended 12/31/06. +6.3 pts VYA +4.8 pts VYA +1.2 pts VYA

  8. Slide 8: Adams Gaining Category Strength

    Slide 8: Adams Gaining Category Strength

    Source: IRI data for the c/c/a/s market for the 4 weeks ended 12/31/06. Adams Gaining Category Strength Mucinex(r) Mucinex(r) DM Mucinex(r) D Mucinex(r) Children's Liquids Mucinex(r) Children's Mini-Melts Delsym(r) Dollar Share of C/C/A/S Category by Major Product +5.2 points VYA 3.7 3.5 1.2 0.7 0.5

  9. Slide 9: Four Catalysts for Growth

    Slide 9: Four Catalysts for Growth

    Four Catalysts for Growth OTC Portfolio Diversification and Expansion FDA Exclusivity Decision on DM and D New Rx NDA Erdosteine

  10. Slide 10: Accelerated Development and Diversification

    Slide 10: Accelerated Development and Diversification

    Fiscal 2006 Fiscal 2007 Accelerated Development and Diversification Fiscal 2008 Expect to double existing portfolio

  11. Slide 11: Mucinex SE, DM and D launch history and market size

    Slide 11: Mucinex SE, DM and D launch history and market size

    Consumer Advertising February 2006 Competing Product Removal? Competing Product Removal? FDA Exclusivity Decision Pending Consumer Advertising November 2004 Competing Products Removed December 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $20 MM Rx market Consumer Advertising November

  12. Slide 12: Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant

    Slide 12: Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant

    Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant NDA submitted Dec. 2006 600/1200 mg guaifenesin (GGE) combinations Approx. 24 MM cough Rx's/year(1) Two other GGE products in development (1) Source: IMS Health NPA reports - MAT 2/06; MAT 3/06.

  13. Slide 13: Erdosteine

    Slide 13: Erdosteine

    Erdosteine In-licensed mucoregulator compound with a unique profile Improvements in mucociliary clearance, mucus volume, flow characteristics and cough(1) Approved in more than 30 foreign markets; approx. 24 million patient exposures Phase IIb clinical program completed Dec. 2006 400 patients with c

  14. Slide 14: Financials

    Slide 14: Financials

    Financials

  15. Slide 15: 2007 Fiscal Second Quarter Net Sales by Major Product

    Slide 15: 2007 Fiscal Second Quarter Net Sales by Major Product

    2007 Fiscal Second Quarter Net Sales by Major Product $39,224 $30,646 $9,130 $18,475 Acquired 6/06 $12,571 Launched 8/06 ($ in thousands) Accelerating Growth Rate Total Net Sales = $110.6 MM +75% vs. Q2 FY06

  16. Slide 16: Top-Line Diversification Continues

    Slide 16: Top-Line Diversification Continues

    Top-Line Diversification Continues Top-Line Diversification Continues $16.3 MM or ~34% $31.0 MM or ~66% Net Sales growth = $47.3 million

  17. Slide 17: Income Statement Overview

    Slide 17: Income Statement Overview

    Income Statement Overview $110.6 $63.2 $239.1 $160.2 $61.3 Net Sales 75.9% 78.0% 79.4% 80.6% 80.5% Gross Margin % $19.4 17.6% $17.4 27.5% $76.2 32% $44.4 28% $19.7 32% Pretax Income % of Net Sales $12.5 $10.7 $46.4 $27.0 $35.8 Net Income 2006 2005 2006 2005 2004 Three months ended Dec. 31, Years end

  18. Slide 18: Year-Over-Year Operating Expenses: SG&A

    Slide 18: Year-Over-Year Operating Expenses: SG&A

    Year-Over-Year Operating Expenses: SG&A Year-Over-Year Operating Expenses: SG&A Fiscal 2006 SG&A Spend: $99 MM Fiscal 2007 Estimated SG&A Spend: $168 - $172 MM

  19. Slide 19

    Slide 19

  20. Slide 20: Future Growth Drivers

    Slide 20: Future Growth Drivers

    Future Growth Drivers Base-brand Market Share Expansion Successful Children's Mucinex(r) Launch Delsym(r) Acquisition and Growth Portfolio Diversification and Expansion New Combo Products Exclusivity Decision on DM and D Erdosteine Acquisitions/In-licensing Vision: Become a $1 billion company over a

  21. Slide 21: Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference

    Slide 21: Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference

    Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conference February 8, 2007

Source: SEC EDGAR · 8-K filed Feb 8, 2007

More decks from Adams Respiratory Therapeutics Inc